Marksans Pharma Limited has initiated the second phase of its 'Saksham Niveshak' campaign to assist shareholders in claiming unclaimed dividends and updating KYC details. The 100-day campaign is designed to prevent the transfer of unclaimed dividends for the financial years 2018-19 and onwards to the Investor Education and Protection Fund (IEPF). Shareholders are required to submit their claims or relevant documents before June 17, 2026, to secure their entitlements.

The company identified that dividends declared from FY2019 to FY2025 remain unclaimed for certain shareholders. The campaign facilitates the claiming of these amounts and encourages the updating of critical details such as contact information, bank account specifics, and nomination choices. This initiative is intended to promote transparency and investor empowerment by enabling direct claim processing without the involvement of third parties.

Shareholders holding shares in physical form must ensure their KYC details, including PAN linked with Aadhaar, address, mobile number, email, and bank account information, are registered. They are required to submit forms ISR-1, ISR-2, ISR-3, SH-13, and SH-14 along with supporting documents. These forms are available on the websites of the company's Registrar and Transfer Agent (RTA), Bigshare Services Private Limited, and Marksans Pharma Limited.

Those holding shares in electronic form must update or modify their details directly with their respective depository participants. The company has provided contact details for both the RTA and the Company Secretary to assist shareholders with the process. The RTA can be reached at investors@bigshareonline.com , while the Company Secretary is available at companysecretary@marksanspharma.com .

Contact Points for Shareholders

Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of Netherlands-based QliniQ B.V. for a cash consideration of €7.5m. Announced on June 01, 2026, the acquisition is a strategic step to expand Marksans' presence across regulated European markets by establishing direct, owned market-access capabilities in the European Union. The transaction is expected to be completed by June 15, 2026, and is not a related party transaction.

Strategic Rationale

QliniQ B.V. operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions across women's health, dermatology, respiratory care, and other specialty categories. The company provides established sales, marketing, and distribution capabilities in the Netherlands, supported by EU GDP-compliant warehousing and regulatory infrastructure. QliniQ maintains long-standing relationships with wholesalers, pharmacies, hospitals, and insurer-led tender channels, which Marksans aims to leverage for the commercialisation of its existing and future product portfolio. The acquisition will enable Marksans to utilise QliniQ's front-end sales and marketing infrastructure to market products manufactured in India, the UK, and the USA.

Financial Performance of QliniQ B.V.

The target entity has delivered strong profitable growth, reporting a revenue CAGR of approximately 41% between FY2023 and FY2025, while maintaining a debt-free balance sheet. The following table presents QliniQ's key audited financials for the financial year ended December 31, 2025:

Acquisition Details

The acquisition will be funded through cash consideration, with no governmental or regulatory approvals required for the transaction. The Board of Directors of Marksans Pharma approved the strategic move to bolster the company's footprint in European markets. QliniQ's portfolio spans women's health, dermatology, respiratory/ENT, endocrinology, and gastroenterology, with several first-to-market positions.

Albert de Bruin and Raymond Lansink, Board members and Shareholders of QliniQ B.V., expressed confidence in the merger, citing Marksans' track record in product development and commitment to quality. Mark Saldanha, Chairman and Managing Director of Marksans Pharma, highlighted that the acquisition provides direct access to the Netherlands market and enhances the ability to commercialise products across regulated European markets.